Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response. / DBDS Genomic Consortium.
In: European Journal of Neurology, Vol. 30, No. 5, 2023, p. 1425-1434.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response
AU - Petersen, Anja Sofie
AU - Barloese, Mads
AU - Lund, Nunu
AU - Pedersen, Adam Friis
AU - Søborg, Marie Louise Kulas
AU - Chalmer, Mona Ameri
AU - Callesen, Ida
AU - Winsvold, Bendik Slagsvold
AU - Zwart, John Anker
AU - Ostrowski, Sisse Rye
AU - Pedersen, Ole Birger
AU - Sellebjerg, Finn
AU - Søndergaard, Helle Bach
AU - Hansen, Malene Bredahl
AU - Jensen, Rigmor Højland
AU - Hansen, Thomas Folkmann
AU - DBDS Genomic Consortium
N1 - Publisher Copyright: © 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
PY - 2023
Y1 - 2023
N2 - Background and purpose: The response to cluster headache treatments has a high interindividual variation. To date, treatment response has only been assessed by a candidate gene approach and no investigations into metabolic pathways have been performed. Our aim was to investigate the association between the polygenetic risk of cluster headache and treatment response to first-line cluster headache treatments as well as known functional variants of CYP3A4 and the response to verapamil. Further, it was aimed to replicate previous single nucleotide polymorphisms found to be associated with treatment response in cluster headache and/or migraine. Methods: In, 508 cluster headache patients diagnosed according to the International Classification of Headache Disorders were genotyped and participated in a semi-structured interview to evaluate treatment response. Polygenetic risk scores were calculated by the effect retrieved from a meta-analysis of the latest two genome-wide association studies on cluster headache. Results: Inferior treatment response to oxygen, triptans and verapamil is associated with chronicity of cluster headache were confirmed but no evidence was found that a response could be predicted by a high genetic risk of cluster headache. Likewise, verapamil response was not associated with functional variants of CYP3A4. No support of the genetic variants previously reported to be associated with treatment response to triptans or verapamil was found. Conclusion: The clinically relevant variation in treatment response for cluster headache was not influenced by genetic factors in the present study.
AB - Background and purpose: The response to cluster headache treatments has a high interindividual variation. To date, treatment response has only been assessed by a candidate gene approach and no investigations into metabolic pathways have been performed. Our aim was to investigate the association between the polygenetic risk of cluster headache and treatment response to first-line cluster headache treatments as well as known functional variants of CYP3A4 and the response to verapamil. Further, it was aimed to replicate previous single nucleotide polymorphisms found to be associated with treatment response in cluster headache and/or migraine. Methods: In, 508 cluster headache patients diagnosed according to the International Classification of Headache Disorders were genotyped and participated in a semi-structured interview to evaluate treatment response. Polygenetic risk scores were calculated by the effect retrieved from a meta-analysis of the latest two genome-wide association studies on cluster headache. Results: Inferior treatment response to oxygen, triptans and verapamil is associated with chronicity of cluster headache were confirmed but no evidence was found that a response could be predicted by a high genetic risk of cluster headache. Likewise, verapamil response was not associated with functional variants of CYP3A4. No support of the genetic variants previously reported to be associated with treatment response to triptans or verapamil was found. Conclusion: The clinically relevant variation in treatment response for cluster headache was not influenced by genetic factors in the present study.
KW - cluster headache
KW - cytochrome P450 3A
KW - oxygen
KW - polygenetic risk score
KW - sumatriptan
KW - verapamil
U2 - 10.1111/ene.15736
DO - 10.1111/ene.15736
M3 - Journal article
C2 - 36773010
AN - SCOPUS:85150291589
VL - 30
SP - 1425
EP - 1434
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 5
ER -
ID: 359560034